Pitcairn CO Biomarin Pharmaceutical Inc Transaction History

Pitcairn CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 03, 2020	SELL	$71.87 - $131.03 $119,160 - $217,247	-1,658 Closed	0 $0
Q2 2020 Jul 28, 2020	BUY	$79.55 - $124.22 $131,893 - $205,956	1,658 New	1,658 $204,000
Q4 2019 Feb 12, 2020	SELL	$64.27 - $86.37 $233,235 - $313,436	-3,629 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$67.4 - $85.11 $29,790 - $37,618	-442 Reduced 10.86%	3,629 $244,000
Q2 2019 Aug 12, 2019	SELL	$80.35 - $93.9 $13,739 - $16,056	-171 Reduced 4.03%	4,071 $349,000
Q1 2019 May 07, 2019	SELL	$84.2 - $98.62 $14,145 - $16,568	-168 Reduced 3.81%	4,242 $376,000
Q4 2018 Feb 12, 2019	SELL	$80.14 - $106.07 $9,216 - $12,198	-115 Reduced 2.54%	4,410 $375,000
Q3 2018 Nov 02, 2018	SELL	$93.92 - $105.72 $32,590 - $36,684	-347 Reduced 7.12%	4,525 $439,000
Q2 2018 Aug 02, 2018	SELL	$76.01 - $99.03 $3,344 - $4,357	-44 Reduced 0.9%	4,872 $459,000
Q1 2018 May 11, 2018	SELL	$77.67 - $92.63 $16,155 - $19,267	-208 Reduced 4.06%	4,916 $398,000
Q4 2017 Feb 13, 2018	SELL	$80.76 - $95.13 $15,667 - $18,455	-194 Reduced 3.65%	5,124 $457,000
Q3 2017 Nov 03, 2017	BUY	$80.6 - $94.95 $428,630 - $504,944	5,318	5,318 $495,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Pitcairn CO, based on Form 13F filings with the SEC.

Stay updated on Pitcairn CO with notifications on news.